See All Slides - tctmd.com

Slides

Presentation TCT 2014

Yes, It Is a Good Option for Most Anticoagulation Eligible Patients

Presenter: Saibal Kar

September 15, 2014

Presentation TCT 2014

Cobalt-Chromium Sirolimus-Eluting Platforms IV: Firehawk

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, Bo Xu

September 15, 2014

Presentation TCT 2014

TCT 149: Intracoronary Injection of Bone Marrow-Derived Mononuclear Cells, Early or Late After Acute Myocardial Infarction: Long-term Effects on Global Left Ventricular Function Twelve-Month MRI and Long-term Clinical Results of the SWISS-AMI Trial

Presenter: Jonathan M. Hill, Hyo-Soo Kim, Emerson C. Perin, Daniel Suerder, MD

September 15, 2014

Presentation TCT 2014

Ventricular Remodeling and Reverse Remodeling in Heart Failure

Presenter: Vasken Dilsizian, Sunil V. Rao, Jose P.S. Henriques, Richard Smalling

September 15, 2014

Presentation TCT 2014

The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, A. Michael Lincoff

September 15, 2014

Presentation TCT 2014

Cobalt-Chromium Sirolimus-Eluting Platforms III: Inspiron

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, Pedro A. Lemos

September 15, 2014

Presentation TCT 2014

No, It Should Be Limited to Patients with Absolute Anticoagulation Contraindications

Presenter: Jai-Wun Park

September 15, 2014

Presentation TCT 2014

DCB and the Use of Ancillary Devices II: Atherectomy - Insights from The DEFINITE AR Trial

Presenter: Kenneth Rosenfield, Thomas Zeller, Raghu Kolluri, Gunnar Tepe

September 15, 2014

Presentation TCT 2014

Bifurcation Lesion Preparation: Critical Appraisal and Recommendations

Presenter: Yves R. Louvard, Bernhard Reimers, Elvin Kedhi, D. Christopher Metzger

September 15, 2014

Presentation TCT 2014

JenaValve - Technology Review, Clinical Results (JUPITER), AR Applications, and Case Examples

Presenter: Hendrik Treede

September 15, 2014

Advertisement

Slides

Yes, It Is a Good Option for Most Anticoagulation Eligible Patients

Cobalt-Chromium Sirolimus-Eluting Platforms IV: Firehawk

TCT 149: Intracoronary Injection of Bone Marrow-Derived Mononuclear Cells, Early or Late After Acute Myocardial Infarction: Long-term Effects on Global Left Ventricular Function Twelve-Month MRI and Long-term Clinical Results of the SWISS-AMI Trial

Ventricular Remodeling and Reverse Remodeling in Heart Failure

The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology

Cobalt-Chromium Sirolimus-Eluting Platforms III: Inspiron

No, It Should Be Limited to Patients with Absolute Anticoagulation Contraindications

DCB and the Use of Ancillary Devices II: Atherectomy - Insights from The DEFINITE AR Trial

Bifurcation Lesion Preparation: Critical Appraisal and Recommendations

JenaValve - Technology Review, Clinical Results (JUPITER), AR Applications, and Case Examples

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content